logo
The FDA is targeting orange juice. Here's why, and what the science says.

The FDA is targeting orange juice. Here's why, and what the science says.

Boston Globea day ago
Orange juice contains nutrients including calcium and Vitamin C. But some nutritionists argue that's not enough to make up for the unnecessary calories and natural sugars.
'Juices are a dilemma,' said Peter Lurie, the executive director of the nonprofit Center for Science in the Public Interest, which advocates for a healthy and safe food supply.
Get Winter Soup Club
A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter.
Enter Email
Sign Up
The American Academy of Pediatrics recommends instead eating real fruit, which contains more fiber than juice. The association advises against giving fruit juice to infants except to manage constipation. It also advises limiting how much juice parents should give older children, such as no more than 4 ounces
per day
for kids 1 to 3 years old.
Advertisement
'If you're going to have a small amount of juice, it's not going to be anything that anybody's going to worry about,' said Marion Nestle, a retired professor of nutrition, food studies and public health at New York University who called fruit juices 'delicious.'
'When you worry about juice is when it's in large amounts,' she added.
Advertisement
Even though leading orange juice brands do not contain added sugars, high levels of natural sugars can still be harmful, some experts said.
'Orange juice is sugar water,' said Barry Popkin, a professor of nutrition at the University of North Carolina. 'Every juice is essentially sugar water.'
Once touted as part of a balanced breakfast, Americans are souring on orange juice. Consumers have gravitated toward other beverage options seen as healthier. Prices have risen. Production has stalled.
And this has become a problem for Florida's orange producers. The sugar content of the fruit grown in the state has been steadily dropping due to a bacterial disease afflicting the crop, exacerbated after Hurricane Irma struck in 2017. In 2022, Florida trade groups representing the state's citrus growers and citrus juice industry petitioned the FDA to lower the minimum fruit sugar levels for pasteurized orange juice.
The FDA sets a minimum standard for the sugar content in order to call a drink 'pasteurized orange juice,' the kind commonly sold at grocery stores without added sugars. If manufacturers fall below that threshold, they are essentially no longer allowed to call their products 'pasteurized
orange juice."
Florida orange industry groups said lowering that threshold would protect their business and reduce orange imports from other countries while going unnoticed by consumers.
Sugar per serving would lower from 18 grams to 17 grams, according to nutritional label samples provided to the FDA by the industry. Other nutrients would be largely unaffected to the change.
Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary both pledged to examine this proposal during congressional hearings when pressed by Sen. Ashley Moody (R-Florida).
Advertisement
Some nutrition experts said if Kennedy wanted to advance his 'Make America Healthy Again' agenda, which included pledges to improve the diets of children, he should champion more sweeping regulations broadly targeting sugars and sodium.
'If one is serious about sugar in the American diet, we need an across the board approach,' Lurie said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program
BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program

Business Wire

time8 minutes ago

  • Business Wire

BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its TAH System has been accepted into the U.S. Food and Drug Administration's (FDA) prestigious Total Product Life Cycle (TPLC) Advisory Program, also known as the TAP program. This milestone further solidifies BiVACOR's collaboration with the FDA following the TAH's earlier recognition this year as a Breakthrough Device. This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology. The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with urgency and magnitude of our mission. Share The TAP program is a transformative FDA initiative designed to accelerate the development and patient access to high-impact medical technologies. Entry into the program provides BiVACOR with proactive, strategic engagement with the FDA throughout the entire product life cycle, from development to commercialization, supporting more efficient, risk-informed decision-making. TAP participation is reserved for breakthrough-designated devices with the potential to significantly improve patient outcomes for serious or life-threatening conditions. 'Acceptance into the TAP program marks a major milestone not just for BiVACOR, but for the field of mechanical circulatory support as a whole,' said Daniel Timms, Founder and Chief Technology Officer of BiVACOR. 'The BiVACOR TAH has the potential to fundamentally redefine the standard of care for patients with end-stage heart failure. TAP access gives us a powerful framework for working hand-in-hand with the FDA to bring this technology to the patients who need it most.' The BiVACOR TAH is intended for use as a bridge to transplant in adults with severe, irreversible biventricular or univentricular heart failure, particularly for patients who cannot be treated with traditional left ventricular assist devices (LVADs). The system employs a magnetically levitated centrifugal pump, inspired by space and industrial technologies, which provides continuous, pulsatile, and physiologically responsive cardiac support. The FDA's acceptance letter to BiVACOR emphasized that the TAP program's inclusion reflects the agency's confidence in the technology's potential to transform clinical practice. As part of the program, BiVACOR will receive more regulatory guidance, earlier identification of scientific and evidentiary gaps, and greater coordination among stakeholders, including payers and patient advocacy groups. 'This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology,' said William Cohn, MD, BiVACOR Chief Medical Officer and renowned cardiac surgeon. 'The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with the urgency and magnitude of our mission to bring a durable, fully implantable artificial heart to patients with no other options.' The TAP program was established as part of the FDA's efforts to modernize device development oversight and ensure the U.S. remains at the forefront of medical innovation. The program currently operates as a pilot under the Center for Devices and Radiological Health (CDRH), with acceptance based on strict criteria outlined in the Federal Register (87 FR 61605). BiVACOR's participation in TAP follows several recent milestones for the company, including its first-in-human implant as a bridge to support a patient awaiting a cardiac transplant. The company is now progressing toward expanded clinical trials in the U.S. and internationally. For more information on the FDA's TAP program, visit: Participation in the FDA's Total Product Life Cycle Advisory Program (TAP) does not imply FDA approval, clearance, or authorization. Inclusion in the TAP Pilot does not guarantee future marketing authorization or a regulatory outcome. The BiVACOR TAH is currently used as an investigational device and is not approved for commercial use. About BiVACOR BiVACOR ® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at

Obstructive Sleep Apnea Solutions That Go Beyond CPAP
Obstructive Sleep Apnea Solutions That Go Beyond CPAP

Medscape

time8 minutes ago

  • Medscape

Obstructive Sleep Apnea Solutions That Go Beyond CPAP

This transcript has been edited for clarity. Hi, everyone. Dr Chandrasekaran here, and today I am going to talk to you about obstructive sleep apnea. One in five American adults complain of obstructive sleep apnea symptoms in one way or another. This disease is now becoming more recognized, and more awareness is being brought to obstructive sleep apnea, as this can lead to significant long-term consequences, such as right heart failure, cor pulmonale, essential hypertension, or atrial fibrillation untreated. Our mainstay is usually diet, weight loss, and once these fail, we then place a patient on a PAP machine. This is usually a noninvasive mechanical ventilator, whether it's a BiPAP, a CPAP, an AVAPS machine, or even auto-CPAP. These can help patients get the comfortable sleep that they need; however, this has been associated with some issues, such as anxiety and claustrophobia, as the mask can preclude this. The FDA has now recently approved Zepbound for treatment of obstructive sleep apnea patients that do meet criteria with a diagnosis of morbid obesity or hypertension associated with a diagnosis of sleep apnea, defined with a sleep study, with apnea-hypopnea index greater than five. The FDA has also approved Inspire, which is a device that can be implanted and can control the hypoglossal nerve, which can decrease the obstruction that is associated with sleep apnea.

The Mere Sight of a Sick Person Can Trigger Our Immune System
The Mere Sight of a Sick Person Can Trigger Our Immune System

Yahoo

time12 minutes ago

  • Yahoo

The Mere Sight of a Sick Person Can Trigger Our Immune System

The mere sight of a sick person may set off an alarm system in your brain and body, even if they are too far away to infect you. A series of experiments using virtual reality headsets has now revealed just how "exquisitely sensitive" our brains are to symptoms of sickness. When participants saw a virtual avatar at varying distances showing clear signs of illness (like a feverish rash), their brains suddenly kicked into gear and their immune systems were put on high alert. When they saw a healthy, neutral-looking avatar, on the other hand, their brains did not show the same activation patterns, and their bloodwork lacked an immediate elevation in immune markers. Related: Some of these markers are known as innate lymphoid cells (ILCs). ILCs can spike in the blood when the body is directly exposed to a pathogen, but all it took in this case was the sight of a virtual infection and the mere prospect of exposure. "Together, these data show that ILCs react to infections not only when they are detected in the body but also when they are processed as a potential threat approaching the body," write the international team of authors, led by immunologist Sara Trabanelli from the University of Lausanne in Switzerland. When researchers used machine learning to statistically analyze the results of their experiments, they found that the brain's threat-detection activity could largely explain the immune response. After seeing a virtual sick person at a distance, the brains of participants lit up in a unique pattern, which was not seen when the avatar had a fearful expression or a neutral expression. The sick avatars that were furthest away elicited the strongest response from the brain's network. Interestingly, some of these activated areas are the same as those that can be triggered after a flu vaccine is given. The findings suggest that when the brain senses a looming threat, it responds rapidly, triggering activity in brain parts like the hypothalamus, which then communicate with the immune system. This gives the body time to put up a fight. The recent experiments took place among 248 healthy adults in total, and in one of the trials, participants wearing VR were asked to press a button when they felt a touch on their face. When their VR sets featured a virtual sick person, participants pressed the button faster upon feeling the touch than when they saw a neutral or fearful avatar. This suggests that their brains are primed because of the sight of sickness. The anticipation probably evolved as a fight-or-flight response, the researchers suspect, though they caution there's still a lot to resolve, including how perceived infectiousness and disgust interact. "These findings suggest an integrated neuro–immune reaction in humans toward infection threats, not solely following physical contact," conclude the authors. Thanks to our brains for staying vigilant on our behalf. The study was published in Nature Neuroscience. Related News Up to 1 in 5 Americans Think They're Allergic to Penicillin. Most Aren't. The Viral 'Kettlebell Challenge' Could Be Harmful. Do This Instead. The 'Fibermaxxing' Wellness Trend May Pose Health Risks. Here's Why. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store